Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer Who Received Bevacizumab Combined With Chemotherapy for First Line Treatment

NCT04684095 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT04684095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04684095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer Who Received Bevacizumab Combined With Chemotherapy for First Line Treatment
Lead sponsor
Harbin Medical University
Phase
Not applicable
Overall status
Unknown status
Start date
May 26, 2021
Completion date
June 15, 2024
Enrollment
338 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, colorectal cancer metastatic